Durvalumab as Consolidation for Patients LS-SCLC
Durvalumab as Consolidation for Patients LS-SCLC
Recruiting · NCT07055581 · Registry updated 2026-03-27Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Durvalumab as Consolidation for Patients LS-SCLC | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, respiratory system disorder, respiratory tract neoplasm, small cell lung carcinoma | Recruiting | Phase 2 | 2026-03-27 | NCT07055581 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Qian Chu | 4 |
2 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital | Zhengzhou | China | 1 |
| Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology | Wuhan | China | 11 |